Own experience of use of EGFR tyrosine kinase inhibitors and bevacizumab in the treatment of patients with non-small cell lung cancer
- Authors: Kolomeytseva A.A1, Gagarin I.M1, Reutova E.V1, Mochal'nikova V.V1, Mazurenko N.N1, Gorbunova V.A1
-
Affiliations:
- Issue: No 18 (2012)
- Pages: 32-37
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279997
- ID: 279997
Cite item
Abstract
Keywords
Full Text
About the authors
A. A Kolomeytseva
I. M Gagarin
E. V Reutova
V. V Mochal'nikova
N. N Mazurenko
V. A Gorbunova
References
- Статистика злокачественных новообразований в России и странах СНГ в 2007 г. / Под редакцией М.И. Давыдова, Е. М. Аксель // Вестник РОНЦ им. Н. Н. Блохина РАМН 2009. Т. 20. № 3(77). Приложение 1.
- Novello S., Le Chevalier T. Chemotherapy for NCSLC. Part 1: early stage disease. Oncology 2003;17:357-64.
- Sato M., Shames D.S., Gazdar A.F., Minna J.D. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;2:327-43.
- Горбунова В.А., Маренич А.Ф., Михина З.П. и др. Консервативное лечение рака легкого. М., 2005. C. 22-5.
- Socinski M.A. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am 2003;9:207-36.
- Hanna N.,Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
- Носов Д.А. Механизмы регуляции внутриклеточной передачи сигнала и апоптоза: успехи и неудачи целенаправленной терапии. Материалы VIII Российского онкологического конгресса 2004.
- Carta C., et al. Germline Missense Mutations Affecting KRAS Isoform B are Associated with a Severe Noonan Syndrome Phenotype. Am J Hum Genet 2006;79(1):129-35.
- Van Damme N., et al. Epidermal Growth Factor Receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010;10:189.
- Maniatis T. Molecular cloning a laboratory manual/ T. Maniatis, E.E. Fritsh, J. Sambrook//Cold Spring Harbor Labaratory 1982.
- Hicklin D.J., Ellis.LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
- Jackman D.M., et al. Final results of a phase II trial of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma. 413th World Conference on Lung Cancer 2009; Abstract A3.
- Jackman D.M., Yeap B.Y., et al. Phase II Clinical Trial of Chemotherapy-Naive Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2007;25:760-66.
- Mendelson J., Baselga H. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
- Mok T.S., Wu Y.L., et al. Gefitinib or Carboplatin Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med 2009;36:947-57.
- Моисеенко В.М., Проценко С.А. и др. Применение Ирессы (гефитиниба) в качестве терапии первой линии для лечения неоперабельных аденокарцином легкого, содержащих мутацию в гене EGFR // Современная онкология 2010. Т. 12. № 1. C. 60-6.
- Моисеенко Ф.В. Молекулярно-генетические особенности немелкоклеточного рака легкого и их значение для определения эффективной лекарственной терапии. Дисс. канд. мед. наук. СПб., 2009.
- Hirsh V., Ramlau R., von Pawel J., Zatloukal P., et al. Final safety results of B017704 (AVAIL): A phase III randomized study of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in patients (pts) with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27,15s(Suppl.)abstr. 8039.
- Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
- Bennouna J., et al. Everolimus plus erlotinib versus erlotinib alone in previously treated patients with advanced non-small-cell lung cancer (NSCLC). ESMO 2010;Abstract 419.
- Nguyen K.-S.H. Kobayashi S., et al. Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway Clin. Lung Cancer 2009;10(4):281-89.
- Frances A., Shepherd M.D., et al. Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353:123-32.
- Fred R.H., Marileila V.G., et al. Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2006;24: 5034-42.